Clinical Image Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/ophthalmology.2.008
Ocular surface squamous neoplasia treated with topical chemotherapy
Elaine Han1, Carol L. Karp2
- 1University of Miami Miller School of Medicine, Miami, FL 33136, USA
- 2Bascom Palmer Eye Institute, Miami, FL 33136, USA
Corresponding Author
Carol L. Karp, ckarp@med.miami.edu
Received Date: April 09, 2020
Accepted Date: April 21, 2020
Han E, Karp CL. Ocular surface squamous neoplasia treated with topical chemotherapy. Arch Clin Exp Ophthalmol 2020; 2(1):8-9.
Copyright: © 2020 Han E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Presbyopia correcting IOLs and the ocular surface disease… The good, the bad and the ugly
The last two decades were especially fruitful for the refractive surgeons and for the industry who have been showing tremendous development in both understanding and meeting patients’ desire for spectacle independence. Ever since the first trials from Dr. Kenneth Hoffer with his early 1980’s effort in producing a multifocal IOL to the latest achievements from different companies in putting trifocals and EDOF optics to the market.
Ocular surface squamous neoplasia treated with topical chemotherapy
A man in his 90s presented to clinic with a conjunctival lesion on the right eye noticed two months prior. The patient denied pain but endorsed worsening blurry vision. The patient’s past medical history was significant for skin cancer on the right ear removed 3 years ago, and a history of ocular surface lesion removal on one eye approximately 20 years ago that was negative for any neoplasia. Slit lamp photograph revealed a gelatinous and opalescent lesion suspicious for ocular surface squamous neoplasia (OSSN) and the high-resolution optical coherence tomography (HROCT) cut (arrow)
Ocular cystinosis – A review of disease, diagnosis, and future treatment options
Cystinosis is a rare autosomal recessive lysosomal storage disorder, characterised by the intra-lysosomal accumulation of cystine. Cystinosis results from a defect in the CTNS protein, a lysosomal transport protein for cystine. There are three subtypes of cystinosis: infantile nephropathic cystinosis, juvenile nephropathic cystinosis and ocular non-nephropathic cystinosis.
Ocular Manifestation of Familial Adenomatous Polyposis
Gardner Syndrome is a phenotypic variant of Familial Adenomatous Polyposis (FAP) characterized by extracolonic manifestations including pigmented ocular fundus lesions with malignant polyps in the large intestine. We present the case of a 41-year-old female with FAP, who presented with numerous congenital hypertrophy of the retinal pigment epithelium ocular lesions.
Efbemalenograstim alfa, a long-acting granulocyte colony-stimulating factor, a novel dimeric G-CSF Fc fusion protein for reducing the risk of febrile neutropenia following chemotherapy
Chemotherapy?induced neutropenia (CIN) can cause life-threatening complications such as febrile neutropenia (FN) or other infections. Patients who develop FN often require prolonged hospitalizations and treatment with broad-spectrum antibiotics.